Business Description
Jiang Xi Sanxin Medtec Co Ltd
ISIN : CNE100001ZJ1
Share Class Description:
SZSE:300453: Class ACompare
Compare
Traded in other countries / regions
300453.China IPO Date
2015-05-15Description
Jiang Xi Sanxin Medtec Co Ltd is engaged in researching and developing, manufacturing and marketing of medical devices. Its products include four series: blood purification, indwelling catheters, injections, infusion and blood transfusion. Blood purification products are used in clinical dialysis treatment for uremic patients. Indwelling catheter products represented by venous indwelling needles, positive pressure indwelling needles, central venous catheters. Injectable products mainly include self-destructing syringes, retracting self-destructing syringes, conjoined syringes.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.49 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 0.84 | |||||
Interest Coverage | 57.32 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.65 | |||||
Beneish M-Score | -2.98 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.8 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | -32.9 | |||||
3-Year Book Growth Rate | 18 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.03 | |||||
9-Day RSI | 42.24 | |||||
14-Day RSI | 41.78 | |||||
6-1 Month Momentum % | -7.88 | |||||
12-1 Month Momentum % | 0.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.32 | |||||
Quick Ratio | 0.94 | |||||
Cash Ratio | 0.67 | |||||
Days Inventory | 83.93 | |||||
Days Sales Outstanding | 25.31 | |||||
Days Payable | 111.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.31 | |||||
Dividend Payout Ratio | 0.36 | |||||
3-Year Dividend Growth Rate | 45.2 | |||||
Forward Dividend Yield % | 2.31 | |||||
5-Year Yield-on-Cost % | 11.56 | |||||
3-Year Average Share Buyback Ratio | 1.2 | |||||
Shareholder Yield % | -0.52 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 35.19 | |||||
Operating Margin % | 18.81 | |||||
Net Margin % | 15.86 | |||||
FCF Margin % | 8.96 | |||||
ROE % | 18.24 | |||||
ROA % | 11.23 | |||||
ROIC % | 15.77 | |||||
ROC (Joel Greenblatt) % | 30.94 | |||||
ROCE % | 19.3 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 15.34 | |||||
PE Ratio without NRI | 15.45 | |||||
Shiller PE Ratio | 31.9 | |||||
Price-to-Owner-Earnings | 50.64 | |||||
PEG Ratio | 0.45 | |||||
PS Ratio | 2.43 | |||||
PB Ratio | 2.64 | |||||
Price-to-Tangible-Book | 3.19 | |||||
Price-to-Free-Cash-Flow | 27.15 | |||||
Price-to-Operating-Cash-Flow | 8.07 | |||||
EV-to-EBIT | 12.18 | |||||
EV-to-EBITDA | 12.18 | |||||
EV-to-Revenue | 2.4 | |||||
EV-to-FCF | 27.27 | |||||
Price-to-Projected-FCF | 1.47 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.62 | |||||
Price-to-Graham-Number | 1.48 | |||||
Earnings Yield (Greenblatt) % | 8.21 | |||||
FCF Yield % | 3.67 | |||||
Forward Rate of Return (Yacktman) % | 23.22 |